Bayer vs Laboratorios Rovi (BAYN.DE vs ROVI)
Bayer (BAYN.DE) vs Laboratorios Rovi (ROVI) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Bayer (BAYN.DE) and Laboratorios Rovi (ROVI) compete in healthcare and pharma. Here are Bayer and Laboratorios Rovi side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Bayer or Laboratorios Rovi.
Bayer vs Laboratorios Rovi: the figures
| Figure | Bayer | Laboratorios Rovi |
|---|---|---|
| Share price | €54.24 (November 4, 2026) | €63.75 (November 4, 2026) |
| Market cap | €53.3 billion | €3.3 billion |
| P/E (TTM) | N/A | 17.6x |
| Forward P/E | 11.2x | 19.4x |
| Revenue growth (quarter) | +1.2% | +20.0% |
| Net margin (TTM) | -3.8% | 24.0% |
| Net debt / EBITDA | 3.3x | Net cash |
| Dividend yield | 0.22% | 1.52% |
| Beta | 0.81 | 0.29 |
Bayer and Laboratorios Rovi figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Bayer or Laboratorios Rovi figure is not available, and we never estimate it.
3 key differences between Bayer and Laboratorios Rovi
- Profitability: for every 100 of sales, Laboratorios Rovi keeps 24.0 as net profit and Bayer keeps -3.8.
- Growth: Laboratorios Rovi grew sales +20.0% year on year in its latest quarter, against +1.2% for Bayer.
- Debt: Bayer owes 3.3x its annual operating profit (EBITDA), while Laboratorios Rovi holds more cash than debt.
Bayer or Laboratorios Rovi: which fits your profile
- If you want growth: Laboratorios Rovi is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you want income (dividends): Laboratorios Rovi pays the higher dividend relative to its price.
- If you prefer caution: Laboratorios Rovi has less debt relative to its profit, which usually gives more room in a bad year.
Neither Bayer nor Laboratorios Rovi wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Bayer and Laboratorios Rovi make money
Bayer (BAYN.DE)
Bayer reports three divisions: Crop Science, its largest, selling seeds (Dekalb) and crop protection to farmers; Pharmaceuticals, with prescription drugs such as Xarelto, Eylea and Nubeqa; and Consumer Health, with over-the-counter brands like Aspirin, Bepanthen and Claritin. It sells worldwide, with North America and Europe as its main markets. Full Bayer analysis.
Laboratorios Rovi (ROVI)
Rovi has two businesses. Specialty pharmaceuticals, its biggest, sells heparins such as biosimilar enoxaparin and bemiparin, plus drugs like the schizophrenia treatment Okedi. Its contract manufacturing arm produces injectable drugs and vaccines for other drugmakers, including Moderna. Spain is its largest market. Full Laboratorios Rovi analysis.
Frequently asked questions: Bayer vs Laboratorios Rovi
Is Bayer or Laboratorios Rovi the better stock?
Choosing between Bayer and Laboratorios Rovi depends on what you are looking for. Laboratorios Rovi is growing faster right now. Fintols does not tell you whether to buy Bayer or Laboratorios Rovi: it shows you the differences so you can decide.
Which pays a higher dividend, Bayer or Laboratorios Rovi?
As of November 4, 2026, Laboratorios Rovi yields 1.52% and Bayer yields 0.22%. Also check how much of their profit Bayer and Laboratorios Rovi pay out: if it is more than they earn, it cannot last.
Can I own both Bayer and Laboratorios Rovi?
Yes. Many people spread their money across several companies, such as Bayer and Laboratorios Rovi, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Bayer or Laboratorios Rovi.
More comparisons with Bayer or Laboratorios Rovi
More companies like Bayer and Laboratorios Rovi: healthcare and pharma stocks. Educational content about Bayer and Laboratorios Rovi, not investment advice.